CMND Clearmind Medicine Inc.
Price Chart
Executive Summary
Clearmind Medicine announced that the Johns Hopkins IRB approved advancing its Phase I/II CMND-100 trial to Parts B and C, following successful completion of earlier stages. For a $2M market-cap pre-revenue biotech, this is a modest clinical milestone that de-risks the program incrementally but does not change the fundamental risk profile or cash runway.
Actionable Insight
This is a routine clinical milestone for a micro-cap biotech — IRB approvals for Phase I/II continuation are common and do not constitute a value inflection. Monitor for actual dosing data or safety readouts from Parts B/C, which would be more material. The company's extremely low share count (158K shares) means any equity offering would be highly dilutive — watch for capital raises.
Key Facts
- Johns Hopkins Medicine IRB granted approval to proceed with Parts B and C of the CMND-100 Phase I/II clinical trial for Alcohol Use Disorder
- The trial is titled 'A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and AUD Subjects: Parts A, B, and C'
- No financial terms, enrollment numbers, dosing data, or timeline for completion were disclosed
- Company had 158,076 common shares outstanding as of January 19, 2026, per the 20-F filed January 2026
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage company with $2M market cap
Risk Factors
- No disclosed cash runway or financing plans — company may need to raise capital to fund Parts B and C
- Clinical-stage biotech with no approved products or revenue; any safety signal could halt the program
- Extremely low market cap ($2M) and share count (158K) make the stock highly volatile and susceptible to dilution
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-060791 |
| Document: ea029214102ex99-1.htm | 0001213900-26-060791 |
| Document: 0001213900-26-060791-index-headers.html | 0001213900-26-060791 |
| Document: 0001213900-26-060791-index.html | 0001213900-26-060791 |
| Document: 0001213900-26-060791.txt | 0001213900-26-060791 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 18, 2026
2d ago
|
6-K
| $3.07 awaiting T+1 | awaiting T+1 | — | $3.07 (−0.00%) |
|
Jun 18, 2026
2d ago
|
Press Release
| $3.05 awaiting T+1 | awaiting T+1 | — | $3.07 (+0.66%) |
|
Jun 16, 2026
4d ago
|
6-K
| $3.14 $3.14 | · 0.00% | ▲ +1.25% | $3.07 (−2.23%) |
|
Jun 12, 2026
8d ago
|
3
| $3.37 $3.14 | ▼ −6.82% | ▼ −6.23% | $3.07 (−8.90%) |
|
Jun 5, 2026
15d ago
|
Press Release
| $3.98 $3.79 | ▼ −4.77% | ▼ −5.00% | $3.07 (−22.86%) |
|
May 29, 2026
22d ago
|
6-K
| $3.58 $3.17 | ▼ −11.45% | ▼ −11.73% | $3.07 (−14.25%) |
|
May 29, 2026
22d ago
|
Press Release
| $3.58 $3.17 | ▼ −11.45% | ▼ −11.73% | $3.07 (−14.25%) |
|
May 26, 2026
25d ago
|
6-K
| $2.59 $2.48 | ▼ −4.25% | ▼ −4.26% | $3.07 (+18.53%) |
|
May 26, 2026
25d ago
|
Press Release
| $2.59 $2.48 | ▼ −4.25% | ▼ −4.26% | $3.07 (+18.53%) |
|
May 19, 2026
4w ago
|
6-K
| $2.36 $2.52 | ▼ −6.78% | ▼ −5.74% | $3.07 (−30.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access